Investor100...w/TELK that is some pretty good data. The trend was toward survival in the treatment arm with the TELIK drug even though the study was not statistically powered for overall survival. Safety data was good as well. The PFS was almost 2 months greater in the treatment arm vs control arm. Not sure it will cause the stock to set fire but it allows the study to move into a potential pivotal Phase III trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.